307 related articles for article (PubMed ID: 34915069)
1. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.
Afonin KA; Dobrovolskaia MA; Ke W; Grodzinski P; Bathe M
Adv Drug Deliv Rev; 2022 Feb; 181():114081. PubMed ID: 34915069
[TBL] [Abstract][Full Text] [Related]
2. Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology.
Afonin KA; Dobrovolskaia MA; Church G; Bathe M
ACS Nano; 2020 Aug; 14(8):9221-9227. PubMed ID: 32706238
[TBL] [Abstract][Full Text] [Related]
3. Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects.
Johnson MB; Chandler M; Afonin KA
Adv Drug Deliv Rev; 2021 Jun; 173():427-438. PubMed ID: 33857556
[TBL] [Abstract][Full Text] [Related]
4. Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.
Panigaj M; Johnson MB; Ke W; McMillan J; Goncharova EA; Chandler M; Afonin KA
ACS Nano; 2019 Nov; 13(11):12301-12321. PubMed ID: 31664817
[TBL] [Abstract][Full Text] [Related]
5. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).
Ke W; Afonin KA
Adv Drug Deliv Rev; 2021 Sep; 176():113835. PubMed ID: 34144087
[TBL] [Abstract][Full Text] [Related]
6. Applications of Spherical Nucleic Acid Nanoparticles as Delivery Systems.
Mokhtarzadeh A; Vahidnezhad H; Youssefian L; Mosafer J; Baradaran B; Uitto J
Trends Mol Med; 2019 Dec; 25(12):1066-1079. PubMed ID: 31703931
[TBL] [Abstract][Full Text] [Related]
7. Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies.
Dobrovolskaia MA
Molecules; 2019 Dec; 24(24):. PubMed ID: 31861154
[TBL] [Abstract][Full Text] [Related]
8. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier.
Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA
Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Nonmodified Wireframe DNA Origami for Acute Toxicity and Biodistribution in Mice.
Wamhoff EC; Knappe GA; Burds AA; Du RR; Neun BW; Difilippantonio S; Sanders C; Edmondson EF; Matta JL; Dobrovolskaia MA; Bathe M
ACS Appl Bio Mater; 2023 May; 6(5):1960-1969. PubMed ID: 37040258
[TBL] [Abstract][Full Text] [Related]
10. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
Milane L; Amiji M
Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells.
Hong E; Halman JR; Shah A; Cedrone E; Truong N; Afonin KA; Dobrovolskaia MA
Molecules; 2019 Mar; 24(6):. PubMed ID: 30897721
[TBL] [Abstract][Full Text] [Related]
12. Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures.
Tran AN; Chandler M; Halman J; Beasock D; Fessler A; McKeough RQ; Lam PA; Furr DP; Wang J; Cedrone E; Dobrovolskaia MA; Dokholyan NV; Trammell SR; Afonin KA
Small; 2022 Apr; 18(13):e2104814. PubMed ID: 35128787
[TBL] [Abstract][Full Text] [Related]
13. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles.
Chandler M; Jain S; Halman J; Hong E; Dobrovolskaia MA; Zakharov AV; Afonin KA
Small; 2022 Nov; 18(46):e2204941. PubMed ID: 36216772
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.
Rinoldi C; Zargarian SS; Nakielski P; Li X; Liguori A; Petronella F; Presutti D; Wang Q; Costantini M; De Sio L; Gualandi C; Ding B; Pierini F
Small Methods; 2021 Sep; 5(9):e2100402. PubMed ID: 34514087
[TBL] [Abstract][Full Text] [Related]
15. Lipid-based nucleic acid therapeutics with in vivo efficacy.
Sufian MA; Ilies MA
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Mar; 15(2):e1856. PubMed ID: 36180107
[TBL] [Abstract][Full Text] [Related]
16. The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells.
Bila D; Radwan Y; Dobrovolskaia MA; Panigaj M; Afonin KA
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299506
[TBL] [Abstract][Full Text] [Related]
17. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs).
Nordmeier S; Ke W; Afonin KA; Portnoy V
Nanomedicine; 2020 Nov; 30():102285. PubMed ID: 32781137
[TBL] [Abstract][Full Text] [Related]
18. Spherical Nucleic Acid Nanoparticles: Therapeutic Potential.
Kapadia CH; Melamed JR; Day ES
BioDrugs; 2018 Aug; 32(4):297-309. PubMed ID: 29959665
[TBL] [Abstract][Full Text] [Related]
19. Engineering DNA scaffolds for delivery of anticancer therapeutics.
Sun W; Gu Z
Biomater Sci; 2015 Jul; 3(7):1018-24. PubMed ID: 26221936
[TBL] [Abstract][Full Text] [Related]
20. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
